Is there a future for TNF promoter polymorphisms?

Genes and Immunity

Volumn 5, Issue 5, 2004, Pages 315-329

  Bayley, J P ^a   Ottenhoff, T H M ^a   Verweij, C L ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Case control; Functional; Polymorphisms; Promoter; TNF

Indexed keywords

ADENINE; GUANINE; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ASTHMA; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; EVIDENCE BASED MEDICINE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATORY DISEASE; LEPROSY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM;

AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COMMUNICABLE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTORS;

EID: 4344579064     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364055     Document Type: Review

References (202)

1. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 26 (Suppl 57): 16-21.
2. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-4031.
3. Rothe J, Lesslauer W, Lotscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
4. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
5. Maini RN, Taylor PC, Paleolog E et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58 (Suppl 1): I56-I60.
6. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
7. van der Linden MW, Huizinga TW, Stoeken DJ. Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods 1998; 218: 63-71.
8. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-406.
9. Westendorp RG, Langermans JA, Huizinga TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
10. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150-154.
11. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998; 51: 605-612.
12. Uglialoro AM, Turbay D, Pesavento PA et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52: 359-367.
13. Brinkman BM, Giphart MJ, Verhoef A et al. Tumor necrosis factor alpha-308 gene variants in relation to major histocompatibility complex alleles and Felty's syndrome. Hum Immunol 1994; 41: 259-266.
14. Wilson AG, di Giovine FS, Blakemore AI. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
15. Brinkman BM, Kaijzel EL, Huizinga TW et al. Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Hum Genet 1995; 96: 493.
16. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995; 211: 833-839.
17. Jongeneel CV. Transcriptional regulation of the tumor necrosis factor alpha gene. Immunobiology 1995; 193: 210-216.
18. Pauli U. Control of tumor necrosis factor gene expression. Crit Rev Eukaryot Gene Exp 1994; 4: 323-344.
19. Caput D, Beutler B, Hartog K et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986; 83: 1670-1674.
20. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
21. Mohan MJ, Seaton T, Mitchell J et al. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 2002; 41: 9462-9469.
22. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7: 231-240.
23. Cytokine Gene Polymorphisms in Human Disease##2002. www.pam.bris.ac.uk/pathandmicro/services/GAI/cytokine4.htm.
24. Wilson AG, de Vries N, van de Putte LB. A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 601-603.
25. Vinasco J, Beraun Y, Nieto A et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49: 74-78.
26. Martinez A, Fernandez-Arquero M, Pascual-Salcedo D et al. Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis. Arthritis Rheum 2000; 43: 1366-1370.
27. Shibue T, Tsuchiya N, Komata T et al. Tumor necrosis factor alpha 5′-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 753-757.
28. Seki N, Kamizono S, Yamada A et al. Polymorphisms in the 5′-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis. Tissue Antigens 1999; 54: 194-197.
29. Danis VA, Millington M, Hyland V et al. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995; 12: 127-133.
30. Yen JH, Chen CJ, Tsai WC et al. Tumor necrosis factor promoter polymorphisms in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2001; 28: 1788-1792.
31. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. J Rheumatol 2002; 29: 212-219.
32. Brinkman BM, Huizinga TW, Kurban SS et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol 1997; 36: 516-521.
33. van Krugten MV, Huizinga TW, Kaijzel EL et al. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun 1999; 1: 91-96.
34. Fabris M, Di PE, D'Elia A et al. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002; 29: 29-33.
35. Hajeer AH, Dababneh A, Makki RF et al. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens 2000; 55: 319-325.
36. Mattey DL, Hassell AB, Dawes PT et al. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1529-1533.
37. Mu H, Chen JJ, Jiang Y et al. Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope. Arthritis Rheum 1999; 42: 438-442.
38. Field M, Gallagher G, Eskdale J et al. Tumor necrosis factor locus polymorphisms in rheumatoid arthritis. Tissue Antigens 1997; 50: 303-307.
39. Udalova IA, Richardson A, Ackerman H. Association of accelerated erosive rheumatoid arthritis with a polymorphism that alters NF-kappaB binding to the TNF promoter region. Rheumatology 2002; 41: 830-831.
40. Zeggini E, Thomson W, Kwiatkowski D et al. Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. Arthritis Rheum 2002; 46: 3304-3311.
41. Mulcahy B, Waldron-Lynch F, McDermott MF et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 1996; 59: 676-683.
42. Ota M, Katsuyama Y, Kimura A et al. A second susceptibility gene for developing rheumatoid arthritis in the human MHC is localized within a 70-kb interval telomeric of the TNF genes in the HLA class III region. Genomics 2001; 71: 263-270.
43. Okamoto K, Makino S, Yoshikawa Y et al. Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am J Hum Genet 2003; 72: 303-312.
44. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654.
45. Mycko M, Kowalski W, Kwinkowski M et al. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84: 198-206.
46. Braun N, Michel U, Ernst BP et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996; 215: 75-78.
47. Lucotte G, Bathelier C, Mercier G. TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele all is associated with the disease in French patients. Mult Scler 2000; 6: 78-80.
48. Sotgiu S, Pugliatti M, Serra C et al. Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-alpha production in Sardinian multiple sclerosis. Ann Neurol 1999; 46: 799-800.
49. Trojano M, Liguori M, De Robertis F et al. Comparison of clinical and demographic features between affected pairs of Italian multiple sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. J Neurol Sci 1999; 162: 194-200.
50. Allcock RJ, de la Concha EG, Fernandez-Arquero M et al. Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster. Hum Immunol 1999; 60: 1266-1273.
51. Ma JJ, Nishimura M, Mine H et al. HLA-DRB1 and tumor necrosis factor gene polymorphisms in Japanese patients with multiple sclerosis. J Neuroimmunol 1998; 92: 109-112.
52. Anlar B, Alikasifoglu M, Kose G et al. Tumor necrosis factor-alpha gene polymorphisms in children with multiple sclerosis. Neuropediatrics 2001; 32: 214-216.
53. Weinshenker BG, Wingerchuk DM, Liu Q et al. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology 1997; 49: 378-385.
54. He B, Navikas V, Lundahl J, Soderstrom M, Hillert J. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. J Neuroimmunol 1995; 63: 143-147.
55. Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. A population-based case-controlstudy of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology 1997; 49: 626-628.
56. Huizinga TW, Westendorp RG, Bollen EL et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72: 149-153.
57. Epplen C, Jackel S, Santos EJ et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997; 41: 341-352.
58. Maurer M, Kruse N, Giess R et al. Gene polymorphism at position -308 of the tumor necrosis factor alpha promotor is not associated with disease progression in multiple sclerosis patients. J Neurol 1999; 246: 949-954.
59. Fernandez-Arquero M, Arroyo R, Rubio A et al. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 1999; 53: 1361-1363.
60. Verjans GM, van der Linden SM, van Eys GJ, de Waal LP, Kijlstra A. Restriction fragment length polymorphism of the tumor necrosis factor region in patients with ankylosing spondylitis. Arthritis Rheum 1991; 34: 486-489.
61. Verjans GM, Brinkman BM, Van Doornik CE, Kijlstra A, Verweij CL. Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol 1994; 97: 45-47.
62. Fraile A, Nieto A, Beraun Y et al. Tumor necrosis factor gene polymorphisms in ankylosing spondylitis. Tissue Antigens 1998; 51: 386-390.
63. Hohler T, Schaper T, Schneider PM, Meyer zum Buschenfelde KH, Marker-Hermann E. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998; 41: 1489-1492.
64. Milicic A, Lindheimer F, Laval S et al. Interethnic studies of TNF polymorphisms confirm the likely presence of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immun 2000; 1: 418-422.
65. Martinez-Borra J, Gonzalez S, Lopez-Vazquez A et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 2000; 61: 131-139.
66. Gonzalez S, Torre-Alonso JC, Martinez-Borra J et al. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients. J Rheumatol 2001; 28: 1288-1293.
67. Kaijzel EL, Brinkman BM, van Krugten MV et al. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. Hum Immunol 1999; 60: 140-144.
68. Chagani T, Pare PD, Zhu S et al. Prevalence of tumor necrosis factor-alpha and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma. Am J Respir Crit Care Med 1999; 160: 278-282.
69. Witte JS, Palmer LJ, O'Connor RD, Hopkins PJ, Hall JM. Relation between tumour necrosis factor polymorphism TNFalpha -308 and risk of asthma. Eur J Hum Genet 2002; 10: 82-85.
70. Winchester EC, Millwood IY, Rand L, Penny MA, Kessling AM. Association of the TNF-alpha -308 (G→A) polymorphism with self-reported history of childhood asthma. Hum Genet 2000; 107: 591-596.
71. Trabetti E, Patuzzo C, Malerba G et al. Association of a lymphotoxin alpha gene polymorphism and atopy in Italian families. J Med Genet 1999; 36: 323-325.
72. Louis R, Leyder E, Malaise M, Bartsch P, Louis E. Lack of association between adult asthma and the tumour necrosis factor alpha -308 polymorphism gene. Eur Respir J 2000; 16: 604-608.
73. Albuquerque RV, Hayden CM, Palmer LJ et al. Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma. Clin Exp Allergy 1998; 28: 578-584.
74. Moffatt MF, Cookson WO. Tumour necrosis factor haplotypes and asthma. Hum Mol Genet 1997; 6: 551-554.
75. Moffatt MF, James A, Ryan G, Musk AW, Cookson WO. Extended tumour necrosis factor/HLA-DR haplotypes and asthma in an Australian population sample. Thorax 1999; 54: 757-761.
76. Li Kam Wa TC, Mansur AH, Britton J et al. Association between -308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma. Clin Exp Allergy 1999; 29: 1204-1208.
77. Cabrera M, Shaw MA, Sharples C et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995; 182: 1259-1264.
78. Karplus TM, Jeronimo SM, Chang H et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70: 6919-6925.
79. Blackwell JM, Black GF, Peacock CS et al. Immunogenetics of leishmanial and mycobacterial infections: the Belem Family Study. Philos Trans Roy Soc London B Biol Sci 1997; 352: 1331-1345.
80. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174: 878-880.
81. Read RC, Camp NJ, di Giovine FS et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000; 182: 1557-1560.
82. Shaw MA, Collins A, Peacock CS et al. Evidence that genetic susceptibility to Mycobacterium tuberculosis in a Brazilian population is under oligogenic control: linkage study of the candidate genes NRAMP1 and TNFA. Tuberc Lung Dis 1997; 78: 35-45.
83. Khoo SH, Pepper L, Snowden N et al. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 1997; 11: 423-428.
84. Roy S, McGuire W, Mascie-Taylor CG et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997; 176: 530-532.
85. Santos AR, Suffys PN, Vanderborght PR et al. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis 2002; 186: 1687-1691.
86. Santos AR, Almeida AS, Suffys PN et al. Tumor necrosis factor promoter polymorphism (TNF2) seems to protect against development of severe forms of leprosy in a pilot study in Brazilian patients. Int J Leprosy Other Mycobact Dis 2000; 68: 325-327.
87. Shaw MA, Donaldson IJ, Collins A et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun 2001; 2: 196-204.
88. Moraes MO, Duppre NC, Suffys PN et al. Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics 2001; 53: 45-47.
89. Sarno EN, Santos AR, Jardim MR et al. Pathogenesis of nerve damage in leprosy: genetic polymorphism regulates the production of TNF alpha. Leprosy Rev 2000; 71 (Suppl): S154-S158.
90. Bochud PY, Hawn THERE, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170: 3451-3454.
91. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-510.
92. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10:Tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. J Infect Dis 2000; 182: 1570-1573.
93. Flori L, Sawadogo S, Esnault C et al. Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. Hum Mol Genet 2003; 12: 375-378.
94. Meyer CG, May J, Luty AJ, Lell B, Kremsner PG. TNFalpha-308A associated with shorter intervals of Plasmodium falciparum reinfections. Tissue Antigens 2002; 59: 287-292.
95. Mombo LE, Ntoumi F, Bisseye C et al. Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg 2003; 68: 186-190.
96. Ubalee R, Suzuki F, Kikuchi M et al. Strong association of a tumor necrosis factor-alpha promoter allele with cerebral malaria in Myanmar. Tissue Antigens 2001; 58: 407-410.
97. Aidoo M, McElroy PD, Kolczak MS et al. Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with preterm delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet Epidemiol 2001; 21: 201-211.
98. Wattavidanage J, Carter R, Perera KL et al. TNFalpha*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin Exp Immunol 1999; 115: 350-355.
99. Stirnadel HA, Stockle M, Felger I et al. Malaria infection and morbidity in infants in relation to genetic polymorphisms in Tanzania. Trop Med Int Health 1999; 4: 187-193.
100. Miyazoe S, Hamasaki K, Nakata K et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-2092.
101. Kim YJ, Lee HS, Yoon JH et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12: 2541-2546.
102. Hohler T, Kruger A, Gerken G et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-582.
103. Yu ML, Dai CY, Chiu CC et al. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003; 59: 35-40.
104. Constantini PK, Wawrzynowicz-Syczewska M, Clare M et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-412.
105. Rosen HR, McHutchison JG, Conrad AJ et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714-720.
106. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-277.
107. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001; 65: 510-516.
108. Knolle PA, Kremp S, Hohler T et al. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up. J Viral Hepatitis 1998; 5: 399-406.
109. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-390.
110. Schiemann U, Glas J, Torok P et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003; 68: 1-4.
111. Tokushige K, Tsuchiya N, Hasegawa K et al. Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV. Am J Gastroenterol 2003; 98: 160-166.
112. Wang Y, Kato N, Hoshida Y et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 65-71.
113. Tambur AR, Ortegel JW, Ben Ari Z et al. Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients. Transplantation 2001; 71: 1475-1480.
114. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-833.
115. Jonsson JR, Hong C, Purdie DM et al. Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. Liver Transplant 2001; 7: 255-263.
116. Lio D, Caruso C, Di Stefano R et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64: 674-680.
117. Hohler T, Kruger A, Gerken G et al. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173-177.
118. Stuber F, Udalova IA, Book M et al. 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46: 42-50.
119. Mira JP, Cariou A, Grall F et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-568.
120. O'Keefe GE, Hybki DL, Munford RS. The G→A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma 2002; 52: 817-825.
121. Tang GJ, Huang SL, Yien HW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000; 28: 2733-2736.
122. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163: 1599-1604.
123. Padyukov L, Hahn-Zoric M, Lau YL, Hanson LA. Different allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians. Genes Immun 2001; 2: 280-283.
124. Zheng C, Huang DR, Bergenbrant S et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000; 109: 39-45.
125. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27: 397-401.
126. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol 1999; 94: 165-171.
127. Wu MS, Huang SP, Chang YT et al. Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 2002; 185: 106-109.
128. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1436-1439.
129. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506-516.
130. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-228.
131. Jeffreys AJ, Kauppi L, Neumann R. Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet 2001; 29: 217-222.
132. Kauppi L, Sajantila A, Jeffreys AJ. Recombination hotspots rather than population history dominate linkage disequilibrium in the MHC class II region. Hum Mol Genet 2003; 12: 33-40.
133. Cullen M, Perfetto SP, Klitz W, Nelson G, Carrington M. High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet 2002; 71: 759-776.
134. Ahmad T, Neville M, Marshall SE et al. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003; 12: 647-656.
135. Pociot F, Wilson AG, Nerup J, Duff GW. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 3050-3053.
136. Jawaheer D, Li W, Graham RR et al. Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 2002; 71: 585-594.
137. Baena A, Leung JY, Sullivan AD et al. TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry. Genes Immun 2002; 3: 482-487.
138. Ackerman H, Usen S, Mott R et al. Haplotypic analysis of the TNF locus by association efficiency and entropy. Genome Biol 2003; 4: R24.
139. Ackerman HC, Ribas G, Jallow M et al. Complex haplotypic structure of the central MHC region flanking TNF in a West African population. Genes Immun 2003; 4: 476-486.
140. de Vries RR. HLA and disease: past, present and future. Neth J Med 1994; 45: 302-308.
141. Tomlinson IP, Bodmer WF. The HLA system and the analysis of multifactorial genetic disease. Trends Genet 1995; 11: 493-498.
142. Newton J, Brown MA, Milicic A et al. The effect of HLA-DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin alpha-tumor necrosis factor haplotype. Arthritis Rheum 2003; 48: 90-96.
143. Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet 1999; 15: 267-272.
144. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2: 245-255.
145. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin N Am 2000; 84: 597-607.
146. Summers KM. Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Hum Mutat 1996; 7: 283-293.
147. Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001; 56: 240-247.
148. Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? Nat Genet 2000; 26: 151-157.
149. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91-99.
150. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405: 847-856.
151. Altshuler D, Kruglyak L, Lander E. Genetic polymorphisms and disease. N Engl J Med 1998; 338: 1626.
152. Dahlman I, Eaves IA, Kosoy R et al. Parameters for reliable results in genetic association studies in common disease. Nat Genet 2002; 30: 149-150.
153. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.
154. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177-182.
155. Editorial. Freely associating. Nat Genet 1999; 22: 1-2.
156. de Jong MM, Nolte IM, de Vries EG et al. The HLA class III subregion is responsible for an increased breast cancer risk. Hum Mol Genet 2003; 12: 2311-2319.
157. Geist LJ, Hopkins HA, Dai LY et al. Cytomegalovirus modulates transcription factors necessary for the activation of the tumor necrosis factor-alpha promoter. Am J Respir Cell Mol Biol 1997; 16: 31-37.
158. Wedel A, Sulski G, Ziegler-Heitbrock HW. CCAAT/enhancer binding protein is involved in the expression of the tumour necrosis factor gene in human monocytes. Cytokine 1996; 8: 335-341.
159. Pope RM, Leutz A, Ness SA. C/EBP beta regulation of the tumor necrosis factor alpha gene. J Clin Invest 1994; 94: 1449-1455.
160. Zagariya A, Mungre S, Lovis R et al. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol 1998; 18: 2815-2824.
161. McCaffrey PG, Goldfeld AE, Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J Biol Chem 1994; 269: 30445-30450.
162. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16: 459-467.
163. Tsai EY, Yie J, Thanos D, Goldfeld AE. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 1996; 16: 5232-5244.
164. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M. Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1994; 1219: 413-421.
165. Leitman DC, Ribeiro RC, Mackow ER, Baxter JD, West BL. Identification of a tumor necrosis factor-responsive element in the tumor necrosis factor alpha gene. J Biol Chem 1991; 266: 9343-9346.
166. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukocyte Biol 1994; 56: 27-35.
167. Novotny V, Prieschl EE, Csonga R, Fabjani G, Baumruker T. Nrf1 in a complex with fosB, c-jun, junD and ATF2 forms the AP1 component at the TNF alpha promoter in stimulated mast cells. Nucleic Acids Res 1998; 26: 5480-5485.
168. Prieschl EE, Novotny V, Csonga R et al. A novel splice variant of the transcription factor Nrf1 interacts with the TNFalpha promoter and stimulates transcription. Nucleic Acids Res 1998; 26: 2291-2297.
169. Kramer B, Wiegmann K, Kronke M. Regulation of the human TNF promoter by the transcription factor Ets. J Biol Chem 1995; 270: 6577-6583.
170. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998; 273: 21178-21186.
171. Kuprash DV, Udalova IA, Turetskaya RL et al. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol 1999; 162: 4045-4052.
172. Myokai F, Takashiba S, Lebo R, Amar S. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci USA 1999; 96: 4518-4523.
173. Takashiba S, Van Dyke TE, Shapira L, Amar S. Lipopolysaccharide-inducible and salicylate-sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect Immun 1995; 63: 1529-1534.
174. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995; 42: 501-504.
175. Tarkowski E, Liljeroth AM, Nilsson A et al. TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD. Neurology 2000; 54: 2077-2081.
176. Somoskovi A, Zissel G, Seitzer U et al. Polymorphisms at position -308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999; 11: 882-887.
177. Turner DM, Grant SC, Lamb WR et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 1995; 60: 1113-1117.
178. Hoffmann SC, Stanley EM, Darrin CE et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-1450.
179. Ito M, Takahashi H, Fuse K et al. Polymorphisms of tumor necrosis factor-alpha and interleukin-10 genes in Japanese patients with idiopathic dilated cardiomyopathy. Jpn Heart J 2000; 41: 183-191.
180. Kubota T, McNamara DM, Wang JJ et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998; 97: 2499-2501.
181. de Jong BA, Westendorp RG, Bakker AM, Huizinga TW. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun 2002; 3: 25-29.
182. Bouma G, Crusius JB, Oudkerk Pool M et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456-463.
183. Fernandes H, Koneru B, Fernandes N et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation 2002; 73: 1886-1891.
184. Fijen JW, Tulleken JE, Hepkema BG et al. The influence of tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphism on the inflammatory response in experimental human endotoxemia. Clin Infect Dis 2001; 33: 1601-1603.
185. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation (see comments). J Inflamm 1995; 46: 32-41.
186. Stuber F, Udalova IA, Book M et al. 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter (see comments). J Inflamm 1995; 46: 42-50.
187. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-3199.
188. Wu WS, McClain KL. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res 1997; 17: 631-635.
189. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46: 32-41.
190. Kaijzel EL, van Krugten MV, Brinkman BM et al. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998; 4: 724-733.
191. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW, Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-alpha promoter. Cytokine 2001; 14: 316-323.
192. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399.
193. Kroeger KM, Steer JH, Joyce DA, Abraham LJ. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000; 12: 110-119.
194. Fong CL, Siddiqui AH, Mark DF. Identification and characterization of a novel repressor site in the human tumor necrosis factor alpha gene. Nucleic Acids Res 1994; 22: 1108-1114.
195. Fong CL, Mark DF. The NF-kappa B-like site in the TNF-alpha repressor element is essential for its repressor function. Biochem Biophys Res Commun 1995; 212: 879-886.
196. Brinkman BM, Huizinga TW, Breedveld FC, Verweij CL. Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Hum Genet 1996; 97: 813-818.
197. Kaijzel EL, Bayley JP, van Krugten MV et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001; 2: 135-144.
198. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003; 33: 469-475.
199. Kochanek S, Radbruch A, Tesch H, Renz D, Doerfler W. DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias. Proc Natl Acad Sci USA 1991; 88: 5759-5763.
200. Kochanek S, Toth M, Dehmel A, Renz D, Doerfler W. Interindividual concordance of methylation profiles in human genes for tumor necrosis factors alpha and beta. Proc Natl Acad Sci USA 1990; 87: 8830-8834.
201. Takei S, Fernandez D, Redford A, Toyoda H. Methylation status of 5′-regulatory region of tumor necrosis factor alpha gene correlates with differentiation stages of monocytes. Biochem Biophys Res Commun 1996; 220: 606-612.
202. Muiznieks I, Doerfler W. The impact of 5′-CG-3′ methylation on the activity of different eukaryotic promoters: a comparative study. FEBS Lett 1994; 344: 251-254.